In OlympiAD, olaparib was administered as a single agent vs chemotherapy in both triple negative and hormone receptor positive, HER2 negative advanced breast cancer. In the primary endpoint analysis, median PFS was longer with olaparib than chemotherapy (7.0 vs 4.2mo; HR 0.58 {0.43-0.80; p<0...